ASJC Scopus subject areas
- Immunology and Allergy
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort. / Haselkorn, Tmirah; Mink, David; Kianifard, Farid; Ortiz, Benjamin; Paknis, Brandee; Lecocq, Jason; Chipps, Bradley E.; Bleecker, Eugene R.In: Annals of Allergy, Asthma and Immunology, 2021.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Predominance of Atopic Asthma in Patients with Severe or Difficult-to-Treat Asthma in the TENOR-II cohort
AU - Haselkorn, Tmirah
AU - Mink, David
AU - Kianifard, Farid
AU - Ortiz, Benjamin
AU - Paknis, Brandee
AU - Lecocq, Jason
AU - Chipps, Bradley E.
AU - Bleecker, Eugene R.
N1 - Funding Information: Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California. Funding Information: We thank Chiranjit Ghosh, PhD, and Rahul Lad, PhD (Novartis), for providing medical writing support for this manuscript. We thank Dr Larry Borish, University of Virginia Health System, Charlottesville, Virginia, and Dr Scott T. Weiss, Channing Division of Network Services, Department of Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, for their contributions to the original analysis. Disclosures: Dr Haselkorn is a former consultant to Novartis Pharmaceuticals Corporation. Dr Ortiz is a former employee and stockholder of Novartis Pharmaceuticals Corporation. Mr Mink is an employee of ICON Clinical Research, a company that receives research funding from Genentech Inc., Novartis, and other pharmaceutical companies. Dr Kianifard, Dr Paknis, and Dr Lecocq are employees of Novartis Pharmaceuticals Corporation. Dr Bleecker reports having clinical trials through his employer, Wake Forest School of Medicine and The University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech Inc., Novartis, Regeneron, and Sanofi Genzyme; receiving personal fees from ERB; and serving as a paid consultant for ALK-Abello, AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, and Teva, outside of the submitted work. Funding: This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, and Genentech Inc, San Francisco, California.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85113876549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113876549&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2021.08.005
DO - 10.1016/j.anai.2021.08.005
M3 - Article
C2 - 34391902
AN - SCOPUS:85113876549
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206